Free Trial
NASDAQ:PRTG

Portage Biotech Q2 2024 Earnings Report

Portage Biotech logo
$8.16 -0.86 (-9.53%)
As of 05/9/2025 03:58 PM Eastern

Portage Biotech EPS Results

Actual EPS
-$5.80
Consensus EPS
-$5.40
Beat/Miss
Missed by -$0.40
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q2 2024
Time
Q2 2024 Earnings Release
Conference Call Date
Tuesday, November 28, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Portage Biotech's Q3 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Portage Biotech Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:PRTG), a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

View Portage Biotech Profile

More Earnings Resources from MarketBeat